NCT06001788 2026-04-14
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Phase 1 Recruiting
Clinical Trials
26 trialsNCT04024761 2026-04-03
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06313437 2026-03-25
Revumenib in Combination With 7+3 + Midostaurin in AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07044544 2026-03-04
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT06408194 2026-02-10
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1 Recruiting
NCT06810583 2026-02-03
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT03829540 2026-01-22
CD4CAR for CD4+ Leukemia and Lymphoma
Indiana University
Phase 1 Recruiting
NCT07347171 2026-01-16
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
Phase 1 Recruiting
NCT06429449 2026-01-15
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Phase 1 Recruiting
NCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT07297173 2025-12-22
Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia
Beijing 302 Hospital
Phase 1 Recruiting
NCT04077307 2025-12-19
MAATEO
Thomas Helleday Foundation
Phase 1 Recruiting
NCT03326921 2025-11-14
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Recruiting
NCT06549790 2025-10-31
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences
Phase 1 Recruiting
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT05983965 2025-09-10
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Recruiting
NCT06340737 2025-08-07
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
Phase 1 Recruiting
NCT03219450 2025-05-22
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05054257 2025-01-06
UHKT-CAR19-01
Institute of Hematology and Blood Transfusion, Czech Republic
Phase 1 Recruiting
NCT06034275 2024-11-15
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma, Inc.
Phase 1 Recruiting
NCT05528887 2022-09-06
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase 1 Recruiting
NCT05043571 2021-09-14
CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia
National University Hospital, Singapore
Phase 1 Recruiting